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Hidradenitis suppurativa (HS) is a chronic, relapsing, and painful inflammatory disease. HS 
patients’ quality of life is severely impaired, and this impairment correlates strongly with their 
pain. Pain in HS can be acute or chronic and has both inflammatory and noninflammatory 
origins. The purpose of this review is to provide a summary of the existing literature regard-
ing pain management in patients with HS. While there are no formal studies investigating 
pain management in HS, existing recommendations are based on general pain guidelines and 
expert opinion. Documentation of pain requires an assessment of the severity and timing of 
the pain. Although anti-inflammatory drugs and surgery for HS can alleviate pain, adjunctive 
pain medications are typically necessary. Topical analgesics, oral acetaminophen, and oral 
nonsteroidal anti-inflammatory drugs are considered first-line agents for the treatment of 
pain in patients with HS. If pain management is ineffective with those agents, oral opiates 
can be considered. In addition, anticonvulsants and selective serotonin reuptake inhibitors/
serotonin-norepinephrine reuptake inhibitors possess neuropathic pain-relieving properties 
that offer not only control of HS-associated pain but beneficial effects on itch and depression. 
There is clearly a need for additional studies on pain management in patients with HS.
INTRODUCTION
Hidradenitis suppurativa (HS) is a chronic painful inflammatory disease with acute exacerba-
tions that may have enhanced pain. The 1994 International Association for the Study of Pain 
(IASP) states: “Pain is an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damage”.1
HS patients’ quality of life is severely impaired and this disability correlates strongly with pain, 
odorous discharge and discomfort.2 The pain has both inflammatory and non-inflammatory 
origin. Chronic pain affects every day functioning leading to extensive burden of the disease.3 
In addition to chronic pain, there is also acute pain during flare-ups.
Different types of pain in HS are reported: nociceptive, neuropathic, inflammatory, non-in-
flammatory (essential), ischemic and pain related to arthritis and depression.4 With no formal 
HS pain studies in the literature, the treatment of pain in HS is based on general pain guide-
lines, expert opinion, and patient preference. The approach to pain management requires: 
documentation of the cause of the pain (ie, inflammatory vs. infectious triggers), the presence 
of external or topical triggers, and the need for surgery (ie, drainage of an abscess, deroofing 
procedures with removal of an amorphous proliferative gelatinous substance, or wider exci-
sion). Although anti-inflammatory medication for HS can decrease pain in HS, additional pain 
medication is usually necessary to manage pain in HS patients.
DOCUMENTATION OF PAIN 
The documentation of pain first requires an assessment of pain severity. The numerical rating 
scale (NRS), where 0 denotes no pain, 5 denotes moderate pain (eg, a bee sting), and 10 
denotes severe pain is a reliable tool that can provide a baseline pain assessment. Patients are 
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also asked to rate the intensity of their pain at the present time. Most individuals can com-
plete activities of daily living with a NRS score of 3 to 4. 
Gathering information about the timing of the pain is significant. Does it occur with acute 
nodules or abscess formation where spontaneous or surgical drainage often relieves suffering? 
Is there a background pain from contracted scars, or chronic low grade inflammation? Does 
friction from tight clothing aggravate the problem? Is there increased discharge and odour 
that may indicate a secondary infection? The description of the pain will distinguish between 
stimulus-dependent nociceptive pain, which is characterized by gnawing, aching, tenderness 
and throbbing, and spontaneous neuropathic pain, which is characterized by burning, sting-
ing, shooting and stabbing. 
TREATMENT  
Topical analgesics, oral acetaminophen and oral NSAIDs are first-line agents for the treatment 
of pain in patients with HS. If pain reduction is insufficient with these therapeutic choices, 
oral opiates may be selected. Caution should be exercised, however, because of the potential 
risk of opioid dependence and withdrawal syndromes. Anticonvulsants, tricyclic and sero-
tonin–norepinephrine reuptake inhibitors (SNRIs) are antidepressant medication that can offer 
long-term pain control, and that respond to any co-occuring depression. Because the man-
agement of pain in patients with HS is complex and challenging, it is vital that it is met with a 
multidisciplinary approach that features collaboration of health care professionals, including a 
pain specialist and psychologist, who are members of a HS team, to achieve optimal care.  
STRATEGY OF PAIN MANAGEMENT 
Treatment of both chronic and acute pain is essential. It is also advised to combine topical and 
systemic agents to increase efficacy. A wide array of topical agents are available, varying in 
compound, vehicles, benefits and limitations.5 Table 1 outlines the topical agents and Table 2 
outlines the systemic agents that are most often used in the management of pain related to 
HS.
Agent Receptor Comment
Dressings, absorptive Nociceptors Use superabsorbent for fluid lock (e.g. sanitary pads, 
abdominal pads). Foam dressings with silicone adhe-
sives/ island dressings. Avoid strong adhesives.
Antibacterials Bacteria associat-
ed MMPs create 
pro-inflammatory 
environment
Clindamycin in studies = oral tetracycline. 
Topical disinfectants like chlorhexidine- decrease bac-
terial numbers. Silver dressings (limited use, postsurgi-
cal procedure, anti-inflammatory, antibacterial).
Ice packs Alternate pain signal Effective but brief duration of acting; inconvenient.
Diclofenac sodium gel 1% Nociceptors Aδ and 
C fibers
Effective and safe for short-term use. Gastrointestinal 
adverse drug reactions are rare.





acaine 1%, diclofenac 
5%, doxepin 3% and 
gabapentin 6%
NMDA. Nociceptors 
Aδ and C fibers.
Histamine and calci-
um channels.
Most effective due to combined mechanisms of action.
Often expensive / drug plans may not cover com-
pounding. Unknown effects of combination (ie, 
stability, dilute preservatives and quenching) make 
substances less active.
Table 1: Topical agents for HS Associated Pain5; MMP, Matrix metalloproteinase; NMDA, N-methyl-D-aspartate
Agent/ Dose Receptor/ Comment
Acetaminophen
Tabs 325, 500 mg
Elixir 80mg/mL
Suppository 325 or 650 mg
Inhibit nitric oxide pathway, increases pain threshold. Start (500 mg x 
2) TID with meals (4 gm max). Good choice for patients > 65 years of 
age or those with GI problems with NSAIDS. Mild/moderate pain. 98% 
absorbed, metabolism liver. Can be used with NSAIDS.
NSAIDS/ASA (OTC)
ASA 325 mg QID
Ibuprofen 400 mg TI
Naproxen 250-500 BID
Diclofenac 50-75 mg TI
Ketoralac 10 mg QID
Indomethacin 25-75 mg q 
8-12h, Sulindac 150-200 q 
12h, COX – 2 Celecoxib 100-
200mg BID
Most non-selective inhibitors cyclo-oxygenase pathway (COX). Require 
inflammation to be effective. Side effects greatest in patients > 65 
years of age (ie, GI bleed, decreased renal function, and aggravation of 
congestive heart failure). If one drug not effective; change to different 
class: Proprionic acid derivatives – Ibuprofen, Naproxen, Acetic acid 
derivatives – Diclofenac, Ketoralac, Indole – Indomethacin, Sulindac, 
COX2- Celecoxib. Can be combined with misoprostol for GI protection. 
Tricyclics
Nortriptyline 10-30 mg
Desipramine 10-30 mg or 
higher when  required for ad-
ditional antidepressant activity  
Works via antinoradrenaline activity. Neuropathic pain agent. Single 
nightly dose facilitates sleep. Can cause double vision, dry mouth, car-
diac arrhythmias and memory retardation. Antidepressant action may 
require 75-150 mg daily. 
Anti – epileptics
Gabapentin 300 mg TID 
increased to max 600 mg/day 
Pregabalin 75 mg BID
increased to max 600 mg/day
Binds to the a-2/d subunit of voltage-dependent calcium channel in 
CNS. Treats neuropathic pain. May help to reduce narcotic dosage. 
Occasional increased risk of depression and suicidal thoughts. May have 
withdrawal effects after long term use. Use with caution in patients 
with renal failure (monoclonus).
SSRI/SNRI
Duloxetine 40-60 mg BID
Venlafaxine 75-235 mg/day
Combination therapy relieves pain/treats depression. Higher doses 
may be associated with weight gain. Side effects > 10% - nausea, dry 
mouth, constipation, insomnia, dizziness. Venlafaxine has less favorable 
side effect profile (e.g. hypertension).
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Agent/ Dose Receptor/ Comment
Opioids
Codeine 15-60 mg q 2-4hr 
(600 mg/24 hr max)
Oxycodone 5 mg PO q 4 hr 
(limit side effects)
Morphine 1 mg up to 60 mg 
q 1 hr (limit side effects). Hy-
dromorphone 1 mg PO q 4 hr 
(limit side effects). Fentanyl – 
patch 12.5, 50, 75, 100 mg/h  
(change q 72 hrs)
Must be familiar with narcotic prescribing/side effects. Risk of addiction, 
double doctoring, drug  diversion. Discuss benefits vs. risk including 
operating machinery and driving. Watch for constipation and confusion 
(especially in the elderly). Need dialog with other physicians, pharma-
cists, patient’s circle of care. Consider agreement letters/contracts. As 
disease is controlled, narcotics need to be shifted to safer long term 
alternative. Start with immediate release (IR), shift to sustained release 
and break through IR. Document use with pain diary.
Table 2: Systemic Agents for HS Associated Pain4,7; ASA, Acetylsalicylic acid; BID, twice daily; CNS, central nervous sys-
tem; COX-2, cyclooxygenase-2; GI, gastrointestinal; IR, immediate release; NSAID, nonsteroidal anti-inflammatory drug; 
OTC, over the counter; RX, prescription; TID, three times daily.
MANAGEMENT OF ACUTE PAIN 
Sharp pain related to acute HS flares accounts for numerous emergency room visits. Acet-
aminophen or NSAIDs can be administered to treat this pain. The maximal effect of anti-in-
flammatory and pain medications is not reached quickly, and therefore acute surgical inter-
ventions (ie, incision and drainage) provide the only rapid solution for pain associated with 
HS flares. Inflammatory nodules can be infiltrated with corticosteroids alone (triamcinolone 
acetonide) or mixed with 1% xylocaine. 
MANAGEMENT OF PAIN IN THE CHRONIC CONTINUOUS PHASE 
The European Dermatology Forum (EDF) guideline recommends management of chronic pain 
in HS according to the World Health Organization (WHO) pain ladder.6,7 The use of acetamin-
ophen and NSAIDs (effect requires active inflammation) in the usual dosages are the first-line 
options to treat nociceptive pain. These medicines produce analgesic and anti-pyretic effects; 
NSAIDs also have addition anti-inflammatory properties. Acetaminophen may provide pain re-
lief by elevating the pain threshold through blocking the nitric-oxide pathway. NSAIDs inhibit 
inflammation and pain through inhibition of the prostaglandin synthesis. Acetaminophen has 
a mild to moderate analgesic effect and is often recommended for patients who cannot toler-
ate NSAIDs. Alternatively, it can be given as an adjunct with NSAIDs to achieve superior pain 
control. Several NSAIDs are available to address HS-related pain, including ibuprofen, naprox-
en, and celecoxib. There is no evidence that one of these agents is superior to another. Before 
prescribing NSAIDs to treat pain, assess the use of any other medications, the presence of 
any existing conditions that may contraindicate NSAID use, such as gastrointestinal bleeding 
or peptic ulcers, and evaluate liver and renal function. Patients with a history of gastrointes-
tinal bleeding or peptic ulcers should be excluded. Clinicians should exercise caution with the 
prescription of cyclooxygenase-2 (COX2) inhibitors because they are contraindicated in the 
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presence of cardiovascular diseases. Chronic use of NSAIDs can cause renal and liver failure, 
as well as prolonged bleeding.7 
Opiates represent second-line therapy in nociceptive pain control. They work by binding 
opioid receptors on both the central and peripheral nervous system. Codeine, hydrocodone, 
morphine and its analogs can be selected to manage severe pain that does not respond to 
first-line agents. The prescribing clinician must be informed about opioid dependence and 
the potential for opiate withdrawal developing after abrupt discontinuation of these drugs. 
Clearly, the use of opiates for the use of pain management in the setting of HS requires expe-
rience and knowledge of the role of these agents in providing pain relief or input from a pain 
specialist.7 
Apart from opiates, other classes of agents can be used for pain management in HS. Anticon-
vulsants, for example, can effectively treat HS-associated neuropathic pain, but given that the 
research suggests that agents such as gabapentin and pregabalin affect the GABA levels in the 
central nervous system and change neural thresholds, prescription of these agents should rest 
in the hands of clinicians who have a knowledge base of these therapies.4 Both gabapentin 
and pregabalin are broadly used in other pain syndromes (e.g. erythromelalgia, perioperative 
pain, and post herpetic neuralgia). Pregabalin has an indication from the European Medicines 
Agency for chronic pain migraine, perioperative pain and neuropathic pain. Both drugs can be 
combined with NSAIDs. A synergistic combination of pregabalin with lidocaine 5% plaster has 
been reported to be useful in other pain syndromes.4
Because >20% of patients with HS suffer from depression and anxiety, the use of second 
generation tricyclic agents (eg, nortriptyline and desipramine) and SNRIs combine neuropathic 
pain control with anti-itch and antidepressant activities. The tricyclic agents, high in anti-nor-
adrenaline activity, are often useful in treating pain, and they should be taken at nighttime at 
low doses to facilitate sleep. Although selective serotonin reuptake inhibitors (SSRIs) can treat 
anxiety disorders, they are not as effective in treating pain. SNRIs dramatically alleviate pain in 
chronic pain sufferers who with or without depression.4
PERIOPERATIVE PAIN MANAGEMENT 
In terms of surgical therapy, at the end of the intervention, the wound edges must be infil-
trated with bupivacaine 5 mg/ml (0.5%). This leads to pain reduction shortly after surgery.8 
After extensive surgery, pain medication is usually prescribed by the anaesthesiologists, whose 
decisions are informed by the most recent post-operative guidelines. In our institutional 
experience (BH, ICJ), postoperative pain management includes oral diclofenac in combination 





In conclusion, pain management for patients with HS is necessary. Inadequate treatment of 
pain may result in adverse events, anxiety and depression.9 For many HS patients, pain is a 
debilitating symptom that can lead to a severely impaired quality of life. Despite the pre-
dominance of pain in HS, there are no formal HS pain studies. In daily practice, a modified 
version of the WHO pain ladder is recommended.7 In addition to topical agents, acetamino-
phen, NSAIDs, and opiates can be used for nociceptive pain control. Neuropathic pain can be 
controlled with several classes of medications, including tricyclic agents, anticonvulsants, and 
SNRIs, all of which offer additional anti-itch and antidepressant actions.4 There is a need for 
additional studies on pain management in patients with HS that should also take into account 
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